Should I buy or sell Oncolytics Biotech stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONCY shares. View ONCY analyst ratings or view top-rated stocks .

What is Oncolytics Biotech's stock price target for 2024?

3 brokers have issued twelve-month price objectives for Oncolytics Biotech's shares. Their ONCY share price targets range from $3.00 to $5.00. On average, they expect the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 270.4% from the stock's current price. View analysts price targets for ONCY or view top-rated stocks among Wall Street analysts .

How have ONCY shares performed in 2024?

Oncolytics Biotech's stock was trading at $1.35 at the start of the year. Since then, ONCY stock has decreased by 20.0% and is now trading at $1.08. View the best growth stocks for 2024 here .

When is Oncolytics Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our ONCY earnings forecast .

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech Inc. (NASDAQ:ONCY) released its quarterly earnings results on Thursday, March, 7th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.07.

What is Brad Thompson's approval rating as Oncolytics Biotech's CEO?

2 employees have rated Oncolytics Biotech Chief Executive Officer Brad Thompson on Glassdoor.com . Brad Thompson has an approval rating of 56% among the company's employees. This puts Brad Thompson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include ADMA Biologics (ADMA) , Matinas BioPharma (MTNB) , Gran Tierra Energy (GTE) , Bionano Genomics (BNGO) , KushCo (KSHB) , Organigram (OGI) , Pennsylvania Real Estate Investment Trust (PEI) , CNBX Pharmaceuticals (CNBX) , Zosano Pharma (ZSAN) and DHT (DHT) .

How do I buy shares of Oncolytics Biotech?

Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ONCY

Oncolytics Biotech (ONCY) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free ONCY Stock Alerts

$1.08

+0.02 (+1.89%)

(As of 04/16/2024 ET)

Compare

Today's Range: $1.01
▼
$1.08
50-Day Range: $0.89
▼
$1.16
52-Week Range: $0.88
▼
$3.39

Volume: 260,227 shs
Average Volume: 390,933 shs
Market Capitalization: $81.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get Oncolytics Biotech alerts:

Oncolytics Biotech MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 270.4% Upside
$4.00 Price Target
Short Interest: Healthy
1.23% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.20
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.32) to ($0.34) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.92 out of 5 stars

Medical Sector

832nd out of 930 stocks

Pharmaceutical Preparations Industry

380th out of 420 stocks

3.5

Analyst's Opinion

Consensus Rating
Oncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Oncolytics Biotech has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.23% of the outstanding shares of Oncolytics Biotech have been sold short.
Short Interest Ratio / Days to Cover
Oncolytics Biotech has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Oncolytics Biotech has recently increased by 1.20%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Oncolytics Biotech does not currently pay a dividend.
Dividend Growth
Oncolytics Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ONCY.

1.0

News and Social Media Coverage

News Sentiment
Oncolytics Biotech has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Oncolytics Biotech this week, compared to 1 article on an average week.
Search Interest
Only 6 people have searched for ONCY on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.10% of the stock of Oncolytics Biotech is held by insiders.
Percentage Held by Institutions
Only 6.82% of the stock of Oncolytics Biotech is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Oncolytics Biotech are expected to decrease in the coming year, from ($0.32) to ($0.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Oncolytics Biotech is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Oncolytics Biotech is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Oncolytics Biotech has a P/B Ratio of 4.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Oncolytics Biotech Stock (NASDAQ:ONCY)

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

ONCY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ONCY Stock News Headlines

April 13, 2024 | theglobeandmail.com

Biotech Breakthroughs Spearhead Fight Against Rising Breast Cancer Cases

April 11, 2024 | finanznachrichten.de

USA News Group: Biotech Innovations Paving the Way in Breast Cancer Fight

April 16, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 11, 2024 | msn.com

Oncolytics seeking FDA meeting to discuss registration-enabling study

April 11, 2024 | prnewswire.com

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

March 14, 2024 | finanznachrichten.de

USA News Group: Biotech's Role in Addressing the Pancreatic Cancer Emergency

March 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment Trials

March 10, 2024 | finance.yahoo.com

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript

April 16, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Oncolytics Biotech Amid Progress and Strategic Clinical Trials

March 8, 2024 | finanznachrichten.de

Oncolytics Biotech Inc.: Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

March 7, 2024 | prnewswire.com

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

March 5, 2024 | prnewswire.com

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

February 28, 2024 | prnewswire.com

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

February 15, 2024 | finance.yahoo.com

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

February 15, 2024 | baystreet.ca

Oncolytics Biotech Inc

February 14, 2024 | finanznachrichten.de

Oncolytics Biotech Inc.: Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

February 14, 2024 | finanznachrichten.de

Oncolytics Biotech® Inc.: Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

February 14, 2024 | finance.yahoo.com

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

February 14, 2024 | prnewswire.com

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

January 23, 2024 | msn.com

Outlook stock rallies on private placement, FDA study agreement

January 9, 2024 | finanznachrichten.de

Oncolytics Biotech® Inc.: Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

January 9, 2024 | finance.yahoo.com

Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

January 4, 2024 | finanznachrichten.de

Oncolytics Biotech® Inc.: Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

January 4, 2024 | finance.yahoo.com

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

December 15, 2023 | finance.yahoo.com

Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

December 11, 2023 | seekingalpha.com

Oncolytics Biotech: Numerous Early Readouts, But Dwindling Reserves

See More Headlines

Receive ONCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/03/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ONCY
CUSIP: N/A
CIK: 1129928
Web: www.oncolyticsbiotech.com
Phone: (403) 670-7377
Fax: 403-283-0858
Employees: 29
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $5.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +284.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,560,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -105.97%
Return on Assets: -72.80%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.01
Quick Ratio: 9.01

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.27 per share
Price / Book: 3.85

Miscellaneous

Outstanding Shares: 75,420,000
Free Float: 75,345,000
Market Cap: $78.44 million
Optionable: Not Optionable
Beta: 1.93

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Matthew C. Coffey M.B.A.
Ph.D., President, CEO & Director
Mr. Kirk J. Look C.A.
CA, Chief Financial Officer
Dr. Thomas C. Heineman M.D.
Ph.D., Chief Medical Officer
Ms. Allison Hagerman P.Eng.
P.M.P., Vice President of Product Development
Ms. Amy Goodowitz Levin
Vice President of Clinical Operations
Jon Patton
Director of Investor Relations & Communication
Mr. John Mark Lievonen BBA
C.M., FCA, LLD, MBA, Consultant

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ONCY Stock Analysis - Frequently Asked Questions

Should I buy or sell Oncolytics Biotech stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONCY shares.
View ONCY analyst ratings or view top-rated stocks.
What is Oncolytics Biotech's stock price target for 2024?: 3 brokers have issued twelve-month price objectives for Oncolytics Biotech's shares. Their ONCY share price targets range from $3.00 to $5.00. On average, they expect the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 270.4% from the stock's current price.
View analysts price targets for ONCY or view top-rated stocks among Wall Street analysts.
How have ONCY shares performed in 2024?: Oncolytics Biotech's stock was trading at $1.35 at the start of the year. Since then, ONCY stock has decreased by 20.0% and is now trading at $1.08.
View the best growth stocks for 2024 here.
When is Oncolytics Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our ONCY earnings forecast.

How were Oncolytics Biotech's earnings last quarter?: Oncolytics Biotech Inc. (NASDAQ:ONCY) released its quarterly earnings results on Thursday, March, 7th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.07.
What is Brad Thompson's approval rating as Oncolytics Biotech's CEO?: 2 employees have rated Oncolytics Biotech Chief Executive Officer Brad Thompson on Glassdoor.com. Brad Thompson has an approval rating of 56% among the company's employees. This puts Brad Thompson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Oncolytics Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), KushCo (KSHB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).
How do I buy shares of Oncolytics Biotech?: Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ONCY) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Oncolytics Biotech (ONCY) Stock Price, News & Analysis

Oncolytics Biotech MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Oncolytics Biotech Stock (NASDAQ:ONCY)

ONCY Stock Price History

ONCY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ONCY Stock Analysis - Frequently Asked Questions

Overall MarketRank^™